My Passport
News and Commentary education Live Coronavirus Dashboard
S&P 500 ETF
0.00%
NASDAQ ETF
0.00%
Dow Jones ETF
0.00%


Nvidia Joining Dow Jones Industrial Average:...
Apple's Services And Silicon Strategy To Fuel...
Lululemon's China Comeback, Analyst Sees 60%...
Disney Creates New Tech Hub For AI and AR
Robinhood Passes 100 Million 2024 Election Co...
Microsoft, Amazon And Apple All Surpassed Est...
Peloton Interactive Analyst Gives A Double Up...
Exxon Mobil Q3 Earnings Impress Analysts With...
The Rise of the Solo General Partner Investor

While modern day venture capital originated in the 1940s, the very first iteration of venture capital (VC) investments--where a general partner (GP) investments capital on behalf of a limited partner (LP)--dates all the way back to the early 1600s with the founding of East India...

  • How are Higher Rates Impacting the Housi...
  • Quantitative Tightening: How the Fed Co...
  • Should Investors Worry About Inflation?
  • How Semiconductors are Made and Why its...
  • What Are NFTs?
    • Inflation: What is it and How to Protect From...
    Short Squeezes Could Lead to Market Dislocati...
    How Google and Facebook Antitrust Lawsuits Co...
    Vaccine News Triggers Growth to Value Rotatio...
    Energy
    Materials
    Industrial
    Finance
    Consumer D...
    Consumer S...
    Informatio...
    Telecommun...
    Health Car...
    Utilities
    Oil
    Gold
    ETFs IPOs Ratings
     
    S&P 500 ETF
    0.00%
    NASDAQ ETF
    0.00%
    Dow Jones ETF
    0.00%
    Search
    News and Commentary
    Education
    Market
    ETFs
    IPOs
    Ratings
    Newsfeed
    My passport
    Login
    Sign up

    SAGE THERAPEUTICS INC (NASDAQ: SAGE)

    Overview
    current price
    $5.81
    $5.81
    change
    0.00 | 0.00%
    0.00 | 0.00%
    Yesterday's Close
    5.81
    open
    0.00
    volume
    0.00 M
    30d. avg volume.
    0.72 M
    1 day
    0.00 - 0.00
    52 weeks
    5.84 - 28.26
    p/e
    0.00
    beta
    0.9208
    market cap
    0.36 B
    dividend yield
    0.00%
    Industry
    -
    SAGE by TradingView
    News and Commentary
    New Drug to Treat Schizophrenia Approved by FDA The U.S. Food and Drug Administration (FDA) has approved Caplyta (lumateperone), a drug developed by Intra-Celullar Therapies Inc.
    Neuro Drug Stocks Rise Following Intra-CellularTherapies' Drug Approval One indisputable trend about the modern world is that people are living longer. In 1950, the average lifespan for an American was 68 years old. Today, it's 78. One result of a lo...
    StockTwits
    StockTwits
    Most Shared
    PepsiCo Adjusts 2024 Revenue Expectations After Mixed Q3 Performance And Global Challenges
    Market Update: Stocks Post Sixth Straight Week of Gains
    US Economy Grows Less Than Expected In Q3, Yet Private Employment Soars By 233,000 In October
    Most Popular
    PepsiCo Adjusts 2024 Revenue Expectations After Mixed Q3 Performance And Global Challenges
    Nuclear Energy Stocks Are Hot: Here's A List Of Tickers To Watch
    Tech, Consumer Discretionary Stocks Fall, Utilities Sector Outperforms On Surprisingly High Inflation, Jobless Claims Data
    popular tags
    Earnings
    Coronavirus
    Apple
    Coronavirus Impact
    Amazon
    Covid-19
    Covid19
    Google
    Tesla
    mobile iOS Android
    social Facebook Twitter Youtube Linkedin Rss Google News
    Passport to Wall Street About Us Contact Advertise Privacy Policy Terms of Service
    Sign Up
    © 2024 Passport to Wall Street
    Quotes are at least 20 minutes delayed

    Join now and unlock premium features

    Already Have An Account?